Dicerna Pharmaceuticals Inc. (DRNA) Upgraded to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) from a hold rating to a buy rating in a report published on Tuesday morning. Zacks Investment Research currently has $6.00 target price on the biopharmaceutical company’s stock.
According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
Several other analysts have also recently issued reports on the company. Stifel Nicolaus restated a buy rating and issued a $13.00 target price on shares of Dicerna Pharmaceuticals in a report on Wednesday, September 28th. Chardan Capital dropped their target price on Dicerna Pharmaceuticals from $4.00 to $3.50 and set a neutral rating for the company in a report on Monday, August 15th. Cowen and Company restated a buy rating on shares of Dicerna Pharmaceuticals in a report on Friday, August 5th. Finally, Leerink Swann restated a buy rating on shares of Dicerna Pharmaceuticals in a report on Thursday, June 30th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $12.30.
Dicerna Pharmaceuticals (NASDAQ:DRNA) opened at 5.43 on Tuesday. The stock’s market cap is $112.69 million. The stock’s 50 day moving average price is $3.76 and its 200 day moving average price is $3.90. Dicerna Pharmaceuticals has a 52 week low of $2.69 and a 52 week high of $15.93.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.84) by $0.09. On average, analysts forecast that Dicerna Pharmaceuticals will post ($3.17) earnings per share for the current year.
Large investors have recently bought and sold shares of the stock. Paloma Partners Management Co bought a new stake in Dicerna Pharmaceuticals during the second quarter worth about $183,000. A.R.T. Advisors LLC bought a new stake in Dicerna Pharmaceuticals during the second quarter worth about $170,000. FMR LLC raised its stake in Dicerna Pharmaceuticals by 0.4% in the second quarter. FMR LLC now owns 3,108,916 shares of the biopharmaceutical company’s stock worth $9,327,000 after buying an additional 11,719 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Dicerna Pharmaceuticals by 44.9% in the second quarter. Dimensional Fund Advisors LP now owns 34,273 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 10,616 shares in the last quarter. Finally, Oxford Asset Management raised its stake in Dicerna Pharmaceuticals by 109.3% in the second quarter. Oxford Asset Management now owns 286,413 shares of the biopharmaceutical company’s stock worth $859,000 after buying an additional 149,560 shares in the last quarter. 62.38% of the stock is currently owned by institutional investors.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Stock Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.